Research programme: chemotherapy drug delivery system - BioLineRx

Drug Profile

Research programme: chemotherapy drug delivery system - BioLineRx

Alternative Names: BL-4010

Latest Information Update: 24 Apr 2014

Price : $50

At a glance

  • Originator PolyGene
  • Developer BioLineRx
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Solid tumours

Most Recent Events

  • 24 Apr 2014 No development reported - Preclinical for Solid tumours in Israel (Intratumoural)
  • 16 Feb 2009 Preclinical development is ongoing in Israel
  • 14 Mar 2007 Preclinical trials in Solid tumours in Israel (Intratumoural)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top